Bluebird Bio Inc (BLUE) 166.51 $BLUE
bluebird bio Announces Participation at the 2015 Wedbush PacGrow Healthcare Conference
Business Wire - Wed Aug 05, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will participate in the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015, with a presentation at 9:10 a.m. ET. The conference is being held at Le Parker Meridien Hotel in New York City.
BLUE: 166.51 (+2.04)
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 6:27AM CDT
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy?
BLUE: 166.51 (+2.04)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34), CELG: 132.72 (+1.64)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), NBIX: 50.44 (+0.88), ISIS: 54.52 (-0.78), SRPT: 32.73 (-0.02), RCPT: 228.97 (+0.97)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 166.51 (+2.04)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 166.51 (+2.04), CELG: 132.72 (+1.64)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 166.51 (+2.04)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 166.51 (+2.04), DRNA: 11.54 (-0.43), ALNY: 127.73 (+1.85), TKMR: 10.83 (+0.58), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 166.51 (+2.04), HZNP: 35.06 (+0.06), AAL: 42.96 (+0.22), SDRL: 7.91 (+0.01), HNT: 69.03 (+0.38)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 17.91 (-0.47), BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), AMGN: 176.44 (+1.64), JUNO: 46.67 (+0.17), SRNE: 20.59 (-0.16), XLRN: 28.86 (-0.15), CELG: 132.72 (+1.64)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 166.51 (+2.04), KITE: 76.50 (+2.96), ADMS: 24.61 (-0.12), ACHN: 8.11 (unch)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 166.51 (+2.04), GILD: 118.66 (-0.21), MNKD: 4.19 (+0.04), PBYI: 90.21 (+1.76), KERX: 7.51 (+0.17), CELG: 132.72 (+1.64)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 166.51 (+2.04), KITE: 76.50 (+2.96), CLLS: 35.00 (+0.22), JUNO: 46.67 (+0.17), CYAD: 55.06 (-0.85), CELG: 132.72 (+1.64)
bluebird bio Announces Participation at the 2015 Wedbush PacGrow Healthcare Conference
Business Wire - Wed Aug 05, 7:30AM CDT
bluebird bio, Inc. (Nasdaq:BLUE) today announced that members of the management team will participate in the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015, with a presentation at 9:10 a.m. ET. The conference is being held at Le Parker Meridien Hotel in New York City.
BLUE: 166.51 (+2.04)
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 30, 6:27AM CDT
bluebird bio (BLUE) Sees Hammer Chart Pattern: Time to Buy?
BLUE: 166.51 (+2.04)
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Regeneron Pharmaceuticals and Exelixis
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34)
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Jul 27, 9:58AM CDT
Biogen's (BIIB) shares lost more than 20% on issues regarding its oral MS treatment as well as disappointing pipeline updates.
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), LGND: 111.25 (+1.94), AMGN: 176.44 (+1.64), REGN: 592.40 (+11.46), EXEL: 6.28 (-0.34), CELG: 132.72 (+1.64)
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
at The Street - Mon Jul 27, 9:30AM CDT
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), NBIX: 50.44 (+0.88), ISIS: 54.52 (-0.78), SRPT: 32.73 (-0.02), RCPT: 228.97 (+0.97)
What's in bluebird bio's Pipeline That Has Investors So Excited?
Brian Feroldi, The Motley Fool - Motley Fool - Sun Jul 19, 9:02AM CDT
Clinical-stage biotechnology company bluebird bio has been a stellar investment for early investors, with the stock up more than 500% since coming public in 2013. However, since bluebird has yet to bring a product to market, investors have been...
BLUE: 166.51 (+2.04)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.51 (-0.17), BLUE: 166.51 (+2.04), AMBA: 115.05 (+0.40), NFLX: 123.71 (+2.56), EYES: 13.89 (-0.26), AMZN: 537.01 (+5.11), ZIOP: 13.96 (+0.56), LNKD: 192.70 (-2.06), FB: 96.44 (+2.38), RCPT: 228.97 (+0.97), LBIO: 7.75 (-0.25), INTC: 29.12 (-0.01), ONTY: 3.62 (-0.01), CELG: 132.72 (+1.64)
Strong Finish Is Key for Market
at The Street - Mon Jul 13, 3:18PM CDT
But there's still the problem of limited upside momentum.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)
Market Action Is Good but the Chase Is Off
at The Street - Mon Jul 13, 11:53AM CDT
There should be a solid close, but it's dead in the meantime.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)
Stock-Picking Action Looks Good for Bulls
at The Street - Mon Jul 13, 9:17AM CDT
Players are happy to set Greece aside, at least temporarily.
BLUE: 166.51 (+2.04), NFLX: 123.71 (+2.56), AMZN: 537.01 (+5.11), TDOC: 33.06 (-1.76), GUID: 9.88 (+0.28), CBM: 53.82 (+1.72), FB: 96.44 (+2.38), LBIO: 7.75 (-0.25), GOOGL: 673.29 (+12.01), MBLY: 59.45 (-0.42), AAPL: 115.40 (+0.76)
Why Shares in Bluebird Bio Slumped By More Than 10% in June
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 08, 8:41AM CDT
A narrowing of its collaboration with biotech Goliath Celgene Corp led shares of bluebird bio to tumble 13.3% in June (via data from Capital IQ ). Casting aside CAR-T Bluebird bio and Celgene had previously been collaborating on the...
BLUE: 166.51 (+2.04), CELG: 132.72 (+1.64)
For The Record
at Investor's Business Daily - Mon Jul 06, 5:44PM CDT
For The Record: The ticker symbol of Bluebird Bio (BLUE) is BLUE. The symbol was wrongly identified in an ETFs story that ran July 2 on page A7.
BLUE: 166.51 (+2.04)
Benitec And Bluebird Bio, Gene Therapy Coming Of Age?
Keith Williams - at Seeking Alpha - Mon Jul 06, 11:24AM CDT
BLUE: 166.51 (+2.04), DRNA: 11.54 (-0.43), ALNY: 127.73 (+1.85), TKMR: 10.83 (+0.58), JUNO: 46.67 (+0.17), CELG: 132.72 (+1.64)
Critical Alerts For Seadrill, Health Net Inc., American Airlines, Horizon Pharma and bluebird bio Inc. Released By InvestorsObserver
PR Newswire - Mon Jul 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SDRL, HNT, AAL, HZNP and BLUE.
BLUE: 166.51 (+2.04), HZNP: 35.06 (+0.06), AAL: 42.96 (+0.22), SDRL: 7.91 (+0.01), HNT: 69.03 (+0.38)
Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
DoctoRx - at Seeking Alpha - Fri Jul 03, 10:12AM CDT
AGTC: 17.91 (-0.47), BLUE: 166.51 (+2.04), BIIB: 335.41 (+5.03), GILD: 118.66 (-0.21), AZN: 34.54 (+0.20), AMGN: 176.44 (+1.64), JUNO: 46.67 (+0.17), SRNE: 20.59 (-0.16), XLRN: 28.86 (-0.15), CELG: 132.72 (+1.64)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 166.51 (+2.04), KITE: 76.50 (+2.96), ADMS: 24.61 (-0.12), ACHN: 8.11 (unch)
Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
at The Street - Thu Jul 02, 11:54AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 166.51 (+2.04), GILD: 118.66 (-0.21), MNKD: 4.19 (+0.04), PBYI: 90.21 (+1.76), KERX: 7.51 (+0.17), CELG: 132.72 (+1.64)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 166.51 (+2.04), KITE: 76.50 (+2.96), CLLS: 35.00 (+0.22), JUNO: 46.67 (+0.17), CYAD: 55.06 (-0.85), CELG: 132.72 (+1.64)
